{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Neuroendocrine+Neoplasm&page=5", "query": { "condition": "Lung Neuroendocrine Neoplasm", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 571, "total_pages": 58, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Neuroendocrine+Neoplasm&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Neuroendocrine+Neoplasm&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T23:05:45.117Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02122861", "title": "Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma - Currently Enrolling", "Non-small Cell Lung Cancer - Enrollment Completed", "Sarcoma - Enrollment Completed" ], "interventions": [ { "name": "ID-LV305", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 47, "start_date": "2014-05-30", "completion_date": "2018-12-15", "has_results": false, "last_update_posted_date": "2019-03-06", "last_synced_at": "2026-10-06T23:05:45.117Z", "location_count": 7, "location_summary": "San Francisco, California • New Haven, Connecticut • Boston, Massachusetts + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02122861" }, { "nct_id": "NCT05557045", "title": "A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Solid Tumor", "Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Anaplastic Thyroid Cancer (ATC)" ], "interventions": [ { "name": "JZP815", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2022-10-10", "completion_date": "2028-04-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-06T23:05:45.117Z", "location_count": 15, "location_summary": "Los Angeles, California • Denver, Colorado • Orlando, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05557045" }, { "nct_id": "NCT05199584", "title": "A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors With PTCH1 Loss-of-function Mutations" ], "interventions": [ { "name": "ENV-101 (taladegib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endeavor Biomedicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-05-24", "completion_date": "2024-02-20", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-06T23:05:45.117Z", "location_count": 16, "location_summary": "Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Zion", "state": "Illinois" }, { "city": "Covington", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05199584" }, { "nct_id": "NCT04244552", "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Ovarian Cancer", "Non-Small Cell Lung Cancer", "Acral Lentiginous Melanoma", "Head and Neck Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "Esophageal Squamous Cell Carcinoma", "Urothelial Carcinoma", "DMMR Colorectal Cancer", "MSI-H Colorectal Cancer", "Melanoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Epithelial Ovarian Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "ATRC-101", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Atreca, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2020-02-11", "completion_date": "2023-11-01", "has_results": false, "last_update_posted_date": "2023-12-29", "last_synced_at": "2026-10-06T23:05:45.117Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04244552" }, { "nct_id": "NCT02318771", "title": "Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Metastatic Renal Cell Cancer", "Recurrent Head and Neck Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Skin Carcinoma", "Stage III Renal Cell Cancer", "Stage IV Lung Cancer", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "Radiation Therapy (RT)", "type": "RADIATION" }, { "name": "MK-3475", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2015-02-05", "completion_date": "2021-03-25", "has_results": false, "last_update_posted_date": "2025-05-15", "last_synced_at": "2026-10-06T23:05:45.117Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02318771" }, { "nct_id": "NCT01931644", "title": "At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "All Diagnosed Health Conditions", "ADD/ADHD", "Alopecia Areata", "Ankylosing Spondylitis", "Asthma", "Atopic Dermatitis Eczema", "Beta Thalassemia", "Bipolar Disorder", "Breast Cancer", "Celiac Disease", "Cervical Cancer", "Chronic Inflammatory Demyelinating Polyneuropathy", "Chronic Kidney Diseases", "Chronic Obstructive Pulmonary Disease", "Colon Cancer", "Colorectal Cancer", "Crohn's Disease", "Cystic Fibrosis", "Depression", "Diabetes Mellitus", "Duchenne Muscular Dystrophy", "Endometriosis", "Epilepsy", "Facioscapulohumeral Muscular Dystrophy", "G6PD Deficiency", "General Anxiety Disorder", "Hepatitis B", "Hereditary Hemorrhagic Telangiectasia", "HIV/AIDS", "Human Papilloma Virus", "Huntington's Disease", "Idiopathic Thrombocytopenic Purpura", "Insomnia", "Kidney Cancer", "Leukemia", "Lung Cancer", "Lupus Nephritis", "Lymphoma", "Melanoma", "Multiple Myeloma", "Multiple Sclerosis", "Myositis", "Myotonic Dystrophy", "Ovarian Cancer", "Pancreatic Cancer", "Parkinson's Disease", "Polycystic Kidney Diseases", "Prostate Cancer", "Psoriasis", "Psoriatic Arthritis", "Rosacea", "Scleroderma", "Sickle Cell Anemia", "Sickle Cell Trait", "Sjogren's Syndrome", "Skin Cancer", "Spinal Muscular Atrophy", "Systemic Lupus Erythematosus", "Thrombotic Thrombocytopenic Purpura", "Trisomy 21", "Ulcerative Colitis" ], "interventions": [], "intervention_types": [], "sponsor": "Sanguine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 17667, "start_date": "2013-07", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-10-06T23:05:45.117Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931644" }, { "nct_id": "NCT02381314", "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "enoblituzumab plus ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2015-03-26", "completion_date": "2018-09-26", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-10-06T23:05:45.117Z", "location_count": 10, "location_summary": "Los Angeles, California • New Haven, Connecticut • Miami Beach, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02381314" }, { "nct_id": "NCT02961283", "title": "Study of ASN003 in Subjects With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Melanoma", "Colorectal Neoplasm", "Carcinoma, Non-small Cell Lung" ], "interventions": [ { "name": "ASN003 ascending doses", "type": "DRUG" }, { "name": "ASN003 MTD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asana BioSciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-10", "completion_date": "2019-02", "has_results": false, "last_update_posted_date": "2023-05-09", "last_synced_at": "2026-10-06T23:05:45.117Z", "location_count": 5, "location_summary": "Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02961283" }, { "nct_id": "NCT04761783", "title": "BESPOKE Study of ctDNA Guided Immunotherapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Melanoma", "Non-small Cell Lung Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Natera, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2021-05-28", "completion_date": "2024-03-30", "has_results": false, "last_update_posted_date": "2024-08-15", "last_synced_at": "2026-10-06T23:05:45.117Z", "location_count": 1, "location_summary": "San Carlos, California", "locations": [ { "city": "San Carlos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04761783" }, { "nct_id": "NCT05614102", "title": "A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BAY2965501", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Platinum-based Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 284, "start_date": "2022-11-04", "completion_date": "2027-04-14", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-06T23:05:45.117Z", "location_count": 3, "location_summary": "Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05614102" } ] }